Rewiring immunity with in vivo CAR T cell engineering.

In vivo CAR T cell engineering can directly generate therapeutic T cells within patients, potentially overcoming manufacturing barriers and expanding access to cancer treatment.

• Why it matters: Current ex vivo CAR T cell therapies face logistical challenges and limited availability, restricting their broader clinical impact. Developing in vivo methods could democratize access and streamline treatment.
• What they did: The authors review the rapidly advancing field, focusing on lymphocyte targeting, pharmacology, biodistribution, and safety considerations, based on emerging research and principles.
• The result: This approach offers promising opportunities for scalable, accessible cancer immunotherapy, while also raising key questions about safety and clinical translation that need to be addressed.